Cross-reactivity of selected benzofurans with commercial amphetamine and ecstasy immunoassays in urine. (December 2017)

• Record Type: Journal Article
• Authors: Gomila, Isabel; Moranta, Concepción; Quesada, Loreto; Pastor, Yolanda; Dastis, Macarena; Torrents, Albert; Elorza, Miguel Ángel; Busardò, Francesco Paolo; Barceló, Bernardino
• Is Part Of: Bioanalysis. Volume 9:Number 22(2017)
• Page Start: 1771
• Page End: 1785
• Publication Date: 2017-12
• Subjects: benzofurans -- cross-reactivity -- immunoassays; Drugs -- Analysis -- Periodicals; 615.19005
• DOI: 10.4155/bio-2017-0191
• Languages: English
• ISSNs: 1757-6180

Abstract

Aim: The aim of this study was to perform a cross-reactivity investigation of six benzofurans with immunoassays (IAs) screening tests for amphetamines and ecstasy in urine samples.Methods: The following benzofuranes were investigated: 5-(2-Methylaminopropyl)Benzofuran (5-MAPB), 5-(2-methylaminopropyl)-2, 3-dihydrobenzofuran (5-MAPDB), 5-(2-Aminopropyl)-Benzofuran (5-APB), 5-(2-Aminopropyl)-2, 3-dihydrobenzofuran (5-APDB), 5-(2-Ethylaminopropyl)Benzofuran (5-EAPB) and 5-(2-Aminoethyl)-2, 3-dihydrobenzofuran (5-AEDB). The study was performed with urine-free spiked samples and authentic urine samples using eight different IAs for amphetamines and ecstasy. Results: All evaluated benzofurans showed cross-reactivity in some of the IAs tested, except for 5-AEDB. Urine samples of an intoxication case involving 5-MAPB, 5-APB and 5-EAPB were also positives in the IAs tested.Conclusion: There is an important variability in the cross-reactivity of the IAs for amphetamine and ecstasy caused by benzofurans depending on the immunoassay employed and the tested compounds.